» Articles » PMID: 31558704

MicroRNA-17 Functions As an Oncogene by Downregulating Smad3 Expression in Hepatocellular Carcinoma

Overview
Journal Cell Death Dis
Date 2019 Sep 28
PMID 31558704
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

The sekelsky mothers against dpp3 (Smad3) functions as a transcriptional modulator activated by transforming growth factor-β (TGF-β). Accumulated evidences indicated that Smad3 played the important roles in carcinogenesis and progression of hepatocellular carcinoma (HCC). Up to now, the regulatory mechanism of Smad3 in HCC still remains unclear. It has been known that some particular microRNAs (miRNAs) involve in carcinogenesis through the regulation of gene expressions with targeting mRNAs. In our study, the unknown candidates of miRNAs that target Smad3 mRNA were searched by using a newly established in vivo approach, the miRNA in vivo precipitation (miRIP). Using a loss-of-function assay, we demonstrated that miR-17 directly targeted Smad3 in HCC cells and inhibition on miR-17 increased Smad3 expression. Furthermore, we found that downregulation on Smad3 expression was consistent with high level of miR-17 in HCC tissues of patients when compared with around normal liver tissues. The manipulated miR-17 silence in HCC cells suppressed their growth of both in vitro and in vivo. Such suppression on cell growth could be recovered through downregulating Smad3. In addition, miR-17 affected cell proliferation through arresting cell cycle in G1 phase. The negative correlation between levels of miR-17 and protein levels of Smad3 was supported by the results of analysis with HCC tissue chip. In summary, for the first time, we confirmed that miR-17 directly targeted Smad3 mRNA and downregulated Smad3 protein expression in HCC. Our results indicated that the increased expression of miR-17 promoted carcinogenesis of HCC through down-regulations of Smad3, suggesting miR-17 might serve as the potential diagnostic and therapeutic targets for clinical HCC.

Citing Articles

Metabolic and Epigenetic Mechanisms in Hepatoblastoma: Insights into Tumor Biology and Therapeutic Targets.

Fu Y, Frances R, Monge C, Desterke C, Marchio A, Pineau P Genes (Basel). 2024; 15(11).

PMID: 39596558 PMC: 11593527. DOI: 10.3390/genes15111358.


Identifying the roles of miR-17 in ciliogenesis and cell cycle.

Alanazi A, Barui A, Mohieldin A, Gupta A, Ramchandran R, Nauli S Front Cell Dev Biol. 2024; 12:1397931.

PMID: 39268086 PMC: 11390542. DOI: 10.3389/fcell.2024.1397931.


The Role of TGF-β/SMAD Signaling in Hepatocellular Carcinoma: from Mechanism to Therapy and Prognosis.

Xin X, Cheng X, Zeng F, Xu Q, Hou L Int J Biol Sci. 2024; 20(4):1436-1451.

PMID: 38385079 PMC: 10878151. DOI: 10.7150/ijbs.89568.


DEJKMDR: miRNA-disease association prediction method based on graph convolutional network.

Gao S, Kuang Z, Duan T, Deng L Front Med (Lausanne). 2023; 10:1234050.

PMID: 37780568 PMC: 10536249. DOI: 10.3389/fmed.2023.1234050.


miR-17-5p slows progression of hepatocellular carcinoma by downregulating TGFβR2.

Liu H, Luo C, Jiang M, Deng Z, Teng Y, Su J Clin Transl Oncol. 2023; 25(10):2960-2971.

PMID: 37024636 DOI: 10.1007/s12094-023-03164-y.


References
1.
Qiu X, Zhu J, Sun Y, Fan K, Yang D, Li G . TR4 nuclear receptor increases prostate cancer invasion via decreasing the miR-373-3p expression to alter TGFβR2/p-Smad3 signals. Oncotarget. 2015; 6(17):15397-409. PMC: 4558159. DOI: 10.18632/oncotarget.3778. View

2.
Braun J, Misiak D, Busch B, Krohn K, Huttelmaier S . Rapid identification of regulatory microRNAs by miTRAP (miRNA trapping by RNA in vitro affinity purification). Nucleic Acids Res. 2014; 42(8):e66. PMC: 4005655. DOI: 10.1093/nar/gku127. View

3.
Li Q, Li S, Wu Y, Gao F . miRNA-708 functions as a tumour suppressor in hepatocellular carcinoma by targeting SMAD3. Oncol Lett. 2017; 14(2):2552-2558. PMC: 5530066. DOI: 10.3892/ol.2017.6429. View

4.
Baek H, Pishvaian M, Tang Y, Kim T, Yang S, Zouhairi M . Transforming growth factor-β adaptor, β2-spectrin, modulates cyclin dependent kinase 4 to reduce development of hepatocellular cancer. Hepatology. 2011; 53(5):1676-84. PMC: 3162321. DOI: 10.1002/hep.24128. View

5.
Han S, Kim H, Seong D, Kim Y, Park Y, Bang Y . Loss of the Smad3 expression increases susceptibility to tumorigenicity in human gastric cancer. Oncogene. 2003; 23(7):1333-41. DOI: 10.1038/sj.onc.1207259. View